Sassa S, de Verneuil H, Anderson K E, Kappas A
Trans Assoc Am Physicians. 1983;96:65-75.
The first complete purification of UROD from human erythrocytes and the characterization of the purified enzyme were described. A single enzyme protein catalyzes the four successive sequential decarboxylations of uroporphyrinogen to yield coproporphyrinogen. The enzyme activity is not directly inhibited by iron; however, it is subject to inhibition in liver cells by a number of chemicals, including environmental pollutants such as dioxin. Studies of erythrocyte UROD in PCT patients indicate that the group of patients now defined as having sporadic PCT may represent two different populations; i.e., those who have normal UROD, and those who have decreased UROD in erythrocytes. Genetic heterogeneity of the UROD defect in PCT is also indicated by the identification of both CRM(-) and CRM(+) mutations in this disorder.
首次描述了从人红细胞中完全纯化尿卟啉原脱羧酶(UROD)以及对纯化酶的特性鉴定。单一酶蛋白催化尿卟啉原连续进行四次脱羧反应生成粪卟啉原。该酶活性不受铁的直接抑制;然而,在肝细胞中它会受到多种化学物质的抑制,包括二噁英等环境污染物。对迟发性皮肤卟啉症(PCT)患者红细胞UROD的研究表明,目前定义为散发性PCT的患者群体可能代表两个不同的人群;即红细胞UROD正常的患者和红细胞UROD降低的患者。PCT中UROD缺陷的遗传异质性也通过该疾病中CRM(-)和CRM(+)突变的鉴定得到了证实。